Insider at Nektar (NASDAQ: NKTR) files to sell 3,867 shares under Rule 144

Rhea-AI Filing Summary

Nektar Therapeutics insider plans to sell common stock under Rule 144. A planned sale of 3,867 common shares through Fidelity Brokerage Services is disclosed, with an aggregate market value of $137,946.37 and 20,341,589 shares of common stock outstanding, to be sold on or about 01/20/2026 on NASDAQ. The shares to be sold were acquired through restricted stock vesting on 08/15/2024, 11/15/2024, and 12/13/2024 as compensation. The notice also reports that Jonathan Zalevsky sold 1,157 common shares on 11/25/2025 for gross proceeds of $68,052.89 during the prior three months.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	3867	137946.37	20341589	01/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2024	Restricted Stock Vesting	Issuer			1	08/15/2024	Compensation
Common	11/15/2024	Restricted Stock Vesting	Issuer			525	11/15/2024	Compensation
Common	12/13/2024	Restricted Stock Vesting	Issuer			3341	12/13/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jonathan Zalevsky 455 Mission Bay Boulevard South San Francisco CA 94158	Common	11/25/2025	1157	68052.89

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for NKTR disclose?

The Form 144 filing discloses a proposed sale of 3,867 shares of Nektar Therapeutics common stock under Rule 144, with an aggregate market value of $137,946.37, to be executed through Fidelity Brokerage Services on or about 01/20/2026 on NASDAQ.

Who is selling Nektar Therapeutics (NKTR) shares and how many?

The filing shows a planned sale of 3,867 common shares of Nektar Therapeutics through Fidelity Brokerage Services. It also lists Jonathan Zalevsky as having sold 1,157 common shares on 11/25/2025 for gross proceeds of $68,052.89 in the past three months.

How were the Nektar Therapeutics shares being sold acquired?

The shares being sold were acquired as restricted stock vesting from the issuer on 08/15/2024, 11/15/2024, and 12/13/2024, in amounts of 1, 525, and 3,341 common shares, respectively, as compensation.

How many Nektar Therapeutics (NKTR) shares are outstanding in this Form 144?

The Form 144 notes that there are 20,341,589 shares of Nektar Therapeutics common stock outstanding in connection with the proposed Rule 144 sale.

On which exchange will the NKTR shares be sold and through which broker?

The proposed 3,867-share sale of Nektar Therapeutics common stock is to be executed through Fidelity Brokerage Services LLC on the NASDAQ stock exchange.

What recent sales of Nektar Therapeutics shares does the Form 144 report?

The filing reports that 1,157 common shares of Nektar Therapeutics were sold on 11/25/2025 for $68,052.89 in gross proceeds by Jonathan Zalevsky during the past three months.